May 03, 2010
Vimovo approved for arthritis patients at risk of NSAID-associated gastric ulcers
This approval was based on results from the six-month PN400-301 and PN400-302 studies. Data from study PN400-301 showed a 4.1% incidence of gastric ulcers in patients taking VIMOVO, compared to 23.1% among patients taking enteric-coated naproxen (p<0.001). Study PN400-302 showed a 7.1% incidence of gastric ulcers among patients taking Vimovo, compared to 24.3% with enteric-coated naproxen (p<0.001).
Vimovo is expected to be made available during summer 2010.
For more information call (800) 237-8898 or visit www.astrazeneca-us.com.